版本:
中国

BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide

June 9 Pfizer Inc

* Astellas and Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide in patients with non-metastatic castration-resistant prostate cancer

* Pfizer Inc- Companies now anticipate prosper top-line results will be disclosed later this year

* Pfizer Inc- previously expected primary completion date for prosper was June 2019

* Says amendment accelerates anticipated prosper top-line results by two years

* Says target sample size reduced to approximately 1,440 patients and estimated primary completion date is June 2017

* Says primary endpoint remains same: metastasis-free survival

* Says main purpose of amendment is to revise plan for analyses of primary and several secondary endpoints Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐